Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake.
about
EGFR/HER-targeted therapeutics in ovarian cancerEndocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycinMolecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases.A novel assay for monitoring internalization of nanocarrier coupled antibodies.An hepatitis B virus surface antigen specific single chain of variable fragment derived from a natural immune antigen binding fragment phage display library is specifically internalized by HepG2.2.15 cells.A quantitative study on the photothermal effect of immuno gold nanocages targeted to breast cancer cellsInhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells.Trastuzumab mediated T-cell response against HER-2/neu overexpressing esophageal adenocarcinoma depends on intact antigen processing machinery.Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy.Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor.Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistanceInduction of protective anti-CTL epitope responses against HER-2-positive breast cancer based on multivalent T7 phage nanoparticles.Primary trastuzumab resistance: new tricks for an old drug.Mimotope vaccines: epitope mimics induce anti-cancer antibodiesTargeting the function of the HER2 oncogene in human cancer therapeutics.Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancerSynthetic peptides as cancer vaccines.Novel pharmacological approaches in the treatment of breast cancer.Targeted tumor killing via an intracellular antibody against erbB-2.Laminin activates the p185HER2 oncoprotein and mediates growth inhibition of breast carcinoma cellsTargeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies.Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin.Improving the efficacy of trastuzumab in breast cancer.Cellular localization of the activated EGFR determines its effect on cell growth in MDA-MB-468 cellsAn antibody-based multifaceted approach targeting the human transferrin receptor for the treatment of B-cell malignancies.Nanovehicular intracellular delivery systems.Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancerCancer therapeutic antibodies come of age: targeting minimal residual disease.Cancer vaccines inducing antibody production: more pros than cons.The GP2 peptide: a HER2/neu-based breast cancer vaccine.Association with membrane protrusions makes ErbB2 an internalization-resistant receptor.Both the epitope specificity and isotype are important in the antitumor effect of monoclonal antibodies against Her-2/neu antigen.Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation.Liquid-phase electron microscopy of molecular drug response in breast cancer cells reveals irresponsive cell subpopulations related to lack of HER2 homodimers.A Cell-Based Internalization and Degradation Assay with an Activatable Fluorescence-Quencher Probe as a Tool for Functional Antibody Screening.Immunization with a novel chimeric peptide representing B and T cell epitopes from HER2 extracellular domain (HER2 ECD) for breast cancer.In vitro assessment of the effects of anti-HER2 monoclonal antibodies on proliferation of HER2-overexpressing breast cancer cells.V-ATPase inhibition overcomes trastuzumab resistance in breast cancer.Dual potency anti-HER2/neu and anti-EGFR anthracycline immunoconjugates in chemotherapeutic-resistant mammary carcinoma combined with cyclosporin A and verapamil P-glycoprotein inhibition.The growth and metastasis of human, HER-2/neu-overexpressing tumor cell lines in male SCID mice.
P2860
Q26863231-AC04C345-3BD1-4AB3-A8CE-62EC4AC5E94EQ30839490-9B4F946D-7C97-4FB5-A2E5-DAD67A553D89Q32062433-D329927B-27AB-47C0-8887-50847A32F1B6Q33259109-82E3A3A7-289E-4D08-AB0C-32F64CB5B4BFQ33288077-588CCD35-4965-4C5F-9D8B-9A2945C4755EQ33407538-346039E0-E39F-4107-9EB8-B990AFFACD24Q33576337-EA833905-B6E8-43C5-839F-FCAAC128A76DQ33701600-A444A145-A431-466E-AB67-81CA8F9DAD54Q33837881-2903ABF1-999D-4F13-83D7-B50F1FB0CAB5Q34088545-C92C8C78-CDC7-471B-9C53-77AB5C74B3C4Q34355748-51A23F8B-4936-4BB0-88B7-3C19DEA5E72CQ34482487-80D66D70-71CD-4365-88EF-4CC852F3A629Q34610251-97A9C331-326A-4217-8473-F631B0382F1BQ34655015-8F7F6F09-5246-4F67-B781-E391B2E9A4EBQ34766486-3B9DF34B-0554-4C38-8EAB-FCF4CA3BF3E9Q34775370-334672C0-6722-4FA6-A9F2-8F061C689A15Q34972916-FCA528FE-D781-449A-9417-3AF9863A93D7Q35143980-6FCC3FC3-EA2D-415C-A94B-5755A455B315Q35769154-1B0D7999-25F6-4EFA-869A-2935E033A69DQ36136193-8E768813-4A06-4B6C-AF89-6B2E462C6111Q36141279-D7D79C2F-1177-4E9D-AF47-7C3BF960F448Q36610604-43041E76-A57D-4B1B-9EF8-8149F03EA2D1Q36788591-ED8B62FB-604C-4F40-AE89-590B31301106Q36990145-0D0DF936-BAB0-464D-96D1-7E5CD4A4E2CEQ37029273-C38DE068-CEFE-4E20-9BBD-1BE82AB2F33DQ37058812-D6BEAEF2-E9A7-4033-8E66-23E9A8CA8013Q37089778-0BCEC8D8-32CC-474F-ADE7-B051888179E4Q37453793-98E0AADC-D711-41EC-B478-2A4959AEB59DQ37932519-555E1E87-3A7F-4313-830D-8F207BFE575FQ37996354-5D82763F-EB8D-46F2-9EFD-5688B7FED852Q38345553-2847F08D-ECB5-4C34-892C-A6F2199FFBBBQ38521735-082467A6-9890-49FE-A138-06C8A5F9DFB2Q38669920-F2820FAC-0A4C-45CE-BC91-EEE60279B9C1Q38695293-9ADA9942-5AA5-48EE-A502-321EA394DD29Q38869540-24ED5656-6394-465C-AF5B-437F7FE0CF07Q38964264-86A8A437-0939-40D4-B07C-828A3C846B5BQ39042958-DDCAE707-D699-4B48-AF03-E12CDEFF7FCFQ39093549-3D6F9B62-07F8-4661-98AF-0326DA906AFAQ39845394-768D338A-DD93-45B1-AAB4-B9A2F0136BBEQ40857892-78C9E3BD-4D2D-407F-A86B-4493D551D715
P2860
Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake.
description
1995 nî lūn-bûn
@nan
1995 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Suppression and promotion of t ...... orrelate with cellular uptake.
@ast
Suppression and promotion of t ...... orrelate with cellular uptake.
@en
Suppression and promotion of t ...... orrelate with cellular uptake.
@nl
type
label
Suppression and promotion of t ...... orrelate with cellular uptake.
@ast
Suppression and promotion of t ...... orrelate with cellular uptake.
@en
Suppression and promotion of t ...... orrelate with cellular uptake.
@nl
prefLabel
Suppression and promotion of t ...... orrelate with cellular uptake.
@ast
Suppression and promotion of t ...... orrelate with cellular uptake.
@en
Suppression and promotion of t ...... orrelate with cellular uptake.
@nl
P2093
P2860
P356
P1476
Suppression and promotion of t ...... orrelate with cellular uptake.
@en
P2093
P2860
P304
P356
10.1073/PNAS.92.8.3353
P407
P577
1995-04-01T00:00:00Z